There are 33 states with laws specifically regulating Hemp to include: Alabama, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Illinois, Indiana, Kentucky, Maine, Maryland, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New York, North Carolina, North Dakota, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Utah, Vermont, Virginia, Washington, and West Virginia.
A type of anxiety marked by fear in some or all social settings (social anxiety disorder). Some early research shows that taking cannabidiol 300 mg daily does not improve anxiety during public speaking in people with social anxiety disorder. However, other early research in people with social anxiety disorder suggests that taking a higher dose (400-600 mg) may improve anxiety associated with public speaking or medical imaging testing. Also, some research in people who do not have social anxiety disorder shows that taking cannabidiol 300 mg might reduce anxiety during public speaking.
CBD oil sourced from hemp is legal all across the U.S when sold as a dietary supplement. Our full-spectrum CBD oil products, when taken daily, add CBD, as well as essential vitamins, minerals, fatty acids, terpenes, flavonoids, and other trace cannabinoids, to your healthy diet. Try one of these healthy recipes for easily adding CBD into your meals.
Because our hemp oil products are categorized as dietary supplements in the United States, we comply with the FDA’s DSHEA guidelines and cannot endorse any specific medical benefits of CBD or our CBD oil. To further comply with FDA regulations, HempMeds® does not list a Recommended Daily Intake (RDI) of our own, nor do we provide a Daily Value (%DV) for any of our products. We encourage you to browse the thousands of reputable studies regarding CBD published online and talk with your doctor to see if a CBD oil supplement is right for you.
Generalized pain, for instance, has dozens upon dozens of high profile research and clinical studies that have been carried out in universities and laboratories around the globe. One of the most well-publicized of these studies took place back in 2008, in which results determined that “cannabinoid analgesics (pain relievers) have generally been well tolerated in clinical trials … with acceptable adverse event profiles (meaning acceptable effectiveness for practical use).